insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ-IRF1-SREBF2 Axis.

Cancer immunology research 2026 Vol.14(3) p. 478-490

Xu L, Zhang X, Lai X, Chen H, Liao S, Chang M, Wu X, Rui W, Yang J, Wang D, Gao C, Fang Z, Zhang J, Li W, Li B, Xia X, Zhou P

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

Tumor cells employ metabolic mechanisms to limit antitumor immunity and promote resistance to immunotherapy.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Xu L, Zhang X, et al. (2026). Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ-IRF1-SREBF2 Axis.. Cancer immunology research, 14(3), 478-490. https://doi.org/10.1158/2326-6066.CIR-25-0242
MLA Xu L, et al.. "Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ-IRF1-SREBF2 Axis.." Cancer immunology research, vol. 14, no. 3, 2026, pp. 478-490.
PMID 41364085
DOI 10.1158/2326-6066.CIR-25-0242

Abstract

Tumor cells employ metabolic mechanisms to limit antitumor immunity and promote resistance to immunotherapy. However, how immunotherapy modulates tumor metabolism remains unclear. In this study, we demonstrated that anti-PD-1 treatment regulated cholesterol biosynthesis in cancer cells through the effector cytokine IFNγ. Mechanistically, IFNγ-induced IRF1 transcriptionally suppresses the expression of SREBF2, a master regulator of cholesterol synthesis. Reduced cholesterol content inhibited tumor growth and sensitized tumor cells to statins, drugs that can lower cholesterol. Overall, our study reveals that IFNγ-mediated inhibition of cholesterol biosynthesis in tumor cells is an important antitumor mechanism of immunotherapy.

MeSH Terms

Interferon Regulatory Factor-1; Animals; Humans; Mice; Cholesterol; Interferon-gamma; Immunotherapy; Sterol Regulatory Element Binding Protein 2; Neoplasms; Cell Line, Tumor; Xenograft Model Antitumor Assays; Female; Signal Transduction

같은 제1저자의 인용 많은 논문 (5)